Multimodal therapy helps horses live their most active lives

No matter a horse’s stage of life, you can recommend a personalized plan to help preserve their joint health, so they can enjoy a lifetime of mobility.

A multimodal approach leverages a range of treatment options to support healthy joints, including:

Treatment with Adequan® i.m. (polysulfated glycosaminoglycan) to protect and restore cartilage in the horse’s joints.

Pain management NSAIDs to relive the pain and inflammation associated with arthritis.

Weight control through a balanced diet and training to keep horses active and moving.

Weight control through a balanced diet and training to keep horses active and moving.

Joint supplements to promote overall joint health.

Don’t underestimate the importance of rest.

Doctor to doctor:
Different approaches to treatment

Watch as Avi Blake, DVM, a technical services veterinarian with American Regent Animal Health, discusses how Adequan i.m. fits into a multimodal approach to managing arthritis in horses.


There is nothing like Adequan i.m.

Adequan i.m. is the only FDA-approved polysulfated glycosaminoglycan for arthritis in horses. It’s proven to work in multiple ways to help maintain joint function:1,2

Reduce inflammation
Restore synovial joint lubrication
Repair joint cartilage
Reverse the disease process

A variety of scientific studies prove that Adequan® i.m. effectively treats degenerative joint disease.3 It features an outstanding safety profile, as proven by scientific studies and more than 30 years of in-field use. There is no generic Adequan i.m.

Not all treatments are created equally

Medical devices

Medical devices are regulated differently by the FDA than prescription drugs and may not have been clinically tested. As such, they cannot be considered as “off-label” or “generic” replacements for drugs. While manufacturers of medical devices must adhere to Quality System Regulations, the requirements for verifying ingredient sources and batch consistency are different from FDA-approved drugs.

Compounded injectables

Compounded drugs are not FDA-approved, although FDA-approved drugs should be used when formulating them. They are also not considered generic drugs. Veterinarians should insist on using a compounding pharmacist who follows FDA Guidelines for Good Compounding Practices.


Supplements are regulated by the FDA differently than prescription drugs. Supplements are not always required to seek the same stringent premarket authorization or approval as drugs. They are not indicated to treat, prevent or cure disease, and cannot make direct medical claims. Unlike FDA-approved drugs, there is no requirement for supplement manufacturers to verify ingredient sources, processes, product quality or batch consistency.

FDA-Approved Drug Products

Download our Product Options Brochure for additional information. Always consult product labels.

Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.

Resources to support your recommendation

Check out our library of resources for handy tools to facilitate your conversations with clients about their horse’s mobility.


Stay informed on Adequan i.m.

Be the first to hear about important news and product information.


  1. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body
  2. fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
  3. Adequan® i.m. (polysulfated glycosaminoglycan) Package Insert. American Regent, Inc.
  4. Adequan® i.m. (polysulfated glycosaminoglycan) NADA 141-038 FOI Summary, 1989.